Connor Landgraf, Co-Founder & CEO
Eko Health is a commercial stage cardiac health technology company that develops connected medical devices powered by proprietary cardiac detection and monitoring software.
“Just as Ring transformed doorbells into home security systems, Eko Health has reinvented the world’s most ubiquitous medical tool into a powerful early disease detection platform, creating the world’s largest install base of professional AI-enabled cardiology devices."
Connor Landgraf
CEO & Co-Founder
Their story
The stethoscope has been a staple of clinical practice for over 200 years, yet its core functionality remained unchanged in the digital era. Recognizing an opportunity to modernize this essential tool, Eko Health was founded to integrate machine learning and connected devices into stethoscope technology, enabling better diagnostics and patient monitoring.
Co-founder and CEO Connor Landgraf, along with Jason Bellet and Tyler Crouch, launched Eko Health after identifying a clinical gap during Landgraf’s senior thesis interviews with healthcare providers. Their mission was to enhance the accuracy and usability of auscultation, particularly in detecting cardiovascular conditions.
Over the past decade, Eko Health has introduced multiple hardware iterations, culminating in the Core 500 — a next-generation digital stethoscope that incorporates advanced audio processing, EKG leads, cloud connectivity, and three FDA-cleared AI-powered algorithms. Today, Eko Health equips over half a million providers with AI-driven diagnostic capabilities to improve patient care.
.avif)
Our partnership
Our investment in Eko Health stemmed from our proactive thesis on connected devices and machine learning-driven clinical algorithms. During our diligence, we saw firsthand how their technology not only resonated with users, but also enabled meaningful clinical advancements, from remote patient monitoring to AI-powered diagnostics.
We first met Connor Landgraf in 2015 and were impressed by the company’s progress over the next two and a half years. Since investing, we have worked closely with their team to refine its go-to-market strategy, expand enterprise adoption, and drive continued innovation in AI-driven cardiopulmonary care.
The team involved
.avif)